Novartis will change CRO relationships ‘over time’ as Senate bill targeting Chinese companies looms
Novartis is “actively” managing its existing relationships with Chinese service providers to mitigate risks if the Biosecure Act passes.
CFO Harry Kirsch told media on Tuesday morning that Novartis currently has “a little bit of connections” to Chinese providers such as CROs, although he did not specify which ones.
“All of this is very manageable and is already actively managed,” Kirsch said. “So, by the time this comes into effect, we will have no exposure from our planning. Very limited at the moment and that will be mitigated in a very reasonable timeframe.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.